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for you. There is a pretty high complication rate of renal failure.
Were most of these patients who came in with renal ischemia as
well, or was this secondary to the procedure?
Dr Timur P. Sarac (Cleveland, Ohio). Most of the patients
who came in with a dissection ﬂap obstructing the renal arteries
with acute renal failure. All the patients in this cohort received
a stent graft for it. We had three patients who we subsequently
reanalyzed and went back and looked at all of our visceral stenting,
and only three patients which were not included in this actually
had stenting of the visceral vessels that we did not put in a thoracic
stent graft. So, our bias is to treat the dissections with the stent
graft and exclude the entry tear and expand the true lumen as
much as possible. Adjunctive stenting of the branch vessel was
necessary in 25% of the patients.
Dr Firas Mussa (New York, NY ). Could you predict why did
those who had left subclavian coverage ended up with a worse
outcome?
Dr Sarac. There is one patient in this series who we covered
the subclavian artery who had a retrograde dissection who expired.
There is no way for me to tell you exactly what the reason is other
than to say that it really is an indication of the extent of the disease,
which acts as a metric for the patients overall condition as these
patients have very diseased aortas and branch vessels.
Dr Richard Cambria (Boston, Mass). Tim, I wanted to ask
a question about how you deﬁned your patient population. I agree
with your conclusion that 20% mortality at 30 days is acceptable in
these patients. When we ﬁrst presented such a series 25 years ago at
this meeting, the mortality for visceral ischemia complicating
dissection was 80%. But my question relates to how you deﬁne
visceral ischemia. Were these radiographic deﬁnitions? Were they
clinically manifest visceral ischemia? And what did the patients
die from?
At 20%, the 30-day mortality is a little higher than the Society
of Vascular Surgery Outcomes Committee objective performance
criteria paper, which had 10% 30-day mortality. So your thoughts
on how the patients might differ.
Dr Sarac. All of the patients all presented with severe symp-
toms of end organ-ischemia. For example, for renal failure, they
were oliguric and had rising creatinine, and for visceral involve-
ment, their lactates were very high, and they had abdominal
pain. So, all these patients truly had emergent operative
indications.
If you look at the number of patients in this group that were
treated within 24 hours of presentation, it was more than one-half
of them. Three of the patients actually underwent dialysis in the
operating room. I think that may have been the difference in
patient population between the two.
Looking at the International Registry of Acute Aortic Dissec-
tions (IRAD) registry, of which there are several excellent reports
out, even in the past 4 months, the cohort of mesenteric patientsand the mortality rate can be as high as 64% in one subsequent
post hoc analysis.
Dr Jean-Paul de Vries (Nieuwegein, The Netherlands). I
want to focus on spinal cord ischemia. Can you give details,
what percentage of the patients have acute spinal cord ischemia
and what percentage suffer from delayed spinal cord ischemia?
And what is your protocol? Does it include cerebrospinal ﬂuid
drainage? Motor-evoked potential and spinal-evoked potential
monitoring?
Dr Sarac. The overall spinal cord ischemia rate was 11.3%. If
the time will allow during the patient’s clinical presentation, we
will get a spinal drain in. That happened in less than one-half of
these patients. Postop all the patients are monitored closely, and
we tend to keep the mean arterial pressure much higher than we
normally would. And this is a high complication rate of 10% or
11% for spinal cord ischemia. One-half of those were paraparesis
that recovered and half of them went on to infarction.
Dr John Ricotta (Washington, DC). Tim, as I saw it, you had
a very high reintervention rate, which certainly has been the expe-
rience of a lot of people including our own experience. How do
you follow these patients?
One of the Achilles’ heels of this whole problem is that the
false lumen does not thrombose in most of the patients. They still
have a diseased aorta, and they do not necessarily get very good
follow-up either for the management of their hypertension or for
late complications, which occurred in about one-half of your
patients. Could you comment about what your protocol is and
how you think we could improve our care paths in that regard.
Dr Sarac. All the patients get a computerized axial tomog-
raphy scan before they leave the intensive care unit, particularly
the ones who have a spinal drain in. They are all seen again at 1
month and then 6 months, every 6 months for the ﬁrst couple
of years.
The point of hypertension control is a big deal. And the reason
I say that is that in most of the patients, as with most of the tertiary
and quaternary places that are doing thoracic endovascular aortic
repair for dissections, it is difﬁcult to manage their hypertension
as surgeons and getting their primary care doctors involved is
important. Certainly, the patients in our institute initially get
admitted to the cardiology unit, and they do a great job of getting
the hypertension under control. But postoperatively, that is a big
deal and we have a big concern for following these patients and
maybe we ought to be doing more for that.
One of the things that we have adopted, and I think more
anecdotal evidence, but Dan and I were talking about the length
and what length of aorta we cover. And I think our bias now is
to cover as much of this as we can. I am interested to see about
the long-term results of the recently reported Petticoat trial, if
that will make a difference when we use a bare-metal stent in the
distal aorta area. But, we do tend to cover as far as we can all
the way down to the celiac artery.
